Clinical Trials Logo

Filter by:
NCT ID: NCT02076139 Completed - Tuberculosis Clinical Trials

Safety and Immunogenicity of Nyaditum Resae® Probiotic to Protect From Tuberculosis

Start date: March 2014
Phase: N/A
Study type: Interventional

This is a double-blind, masked, compared with placebo clinical trial in healthy volunteers with or without tuberculosis infection. This trial aims to study the effect of the probiotic Nyaditum resae® at the level of specific Regulatory T cells (Treg) memory cells one week after the first administration and the global tolerability of the treatment. Nyaditum resae® is a preparation in the form of drinkable vials containing heat-killed environmental mycobacteria. The overall objective of the study is the effect of Nyaditum resae® on immunity, which could reduce the risk of developing active tuberculosis.

NCT ID: NCT02075593 Completed - HIV Infections Clinical Trials

ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection

Start date: December 17, 2014
Phase: Phase 3
Study type: Interventional

In this study, the dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed dose combination (FDC) tablet is being made available to women who become pregnant while participating in study ING117172. Continuation of antiretroviral therapy (ART) is key to both mother and the unborn fetus in order to maintain virologic suppression in the mother (thereby decreasing the risk for maternal disease progression), but also to reduce the risk of maternal-fetal transmission of human immunodeficiency virus type 1 (HIV-1) to her unborn child. This study also offers the first opportunity to investigate the impact of pregnancy on DTG pharmacokinetics (PK). This is an open-label, single arm interventional study. The number of women that will be enrolled into this study cannot be established a priori, as unintended pregnancies cannot be determined in advance. The maximum number of women would include all of those women randomized to DTG/ABC/3TC FDC (approximately 237), though unintended pregnancies in all of these women would not be anticipated.

NCT ID: NCT02075476 Completed - Clinical trials for A02.835.232.087.090.400.400

Effectiveness Between Two Surgical Techniques for Reconstruction of Humeral Proximal Extremity Fractures

Start date: May 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety of two surgical techniques for the treatments of proximal extremity humeral fractures and fractures luxation in three o four fragments of Neer's classification.

NCT ID: NCT02075255 Completed - Asthma Clinical Trials

Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy

Start date: April 28, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to confirm if benralizumab can reduce the use of maintenance OCS in systemic corticosteroid dependent patients with severe refractory asthma with elevated eosinophils.

NCT ID: NCT02074982 Completed - Clinical trials for Chronic Plaque Type Psoriasis

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

Start date: February 25, 2014
Phase: Phase 3
Study type: Interventional

This study will assess efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis

NCT ID: NCT02074657 Completed - Clinical trials for Relapsed/Refractory Paediatric Acute Leukaemia

"LANK-2": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia

LYDIA
Start date: April 2014
Phase: Phase 2
Study type: Interventional

To determine safety profile of immunotherapy with natural killer cells and activated expanded (NKAEs) after salvage chemotherapy in children, adolescents and young adults with relapsed or refractary acute leukemia

NCT ID: NCT02073552 Completed - Clinical trials for Colonoscopy Preparation

Colon Cleansing Quality of Polyethylene Glycol Compared With Polyethylene Glycol Plus Ascorbic Acid.

REPREP1
Start date: May 2014
Phase: Phase 4
Study type: Interventional

The purpose of the study is to assess whether a low volume polyethylene glycol (PEG) plus ascorbic acid based bowel preparation for colonoscopy is not inferior to a large volume polyethylene glycol preparation in subjects with past history of poor bowel preparation

NCT ID: NCT02072824 Completed - Clinical trials for Partial Onset Seizures

A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.

Start date: September 16, 2014
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the effectiveness of 2 doses of pregabalin to reduce seizure frequency as an add on therapy in pediatric subjects 1 month to <4 years of age with refractory partial onset seizures. It is hypothesized that both doses of pregabalin will demonstrate superior efficacy when compared to placebo by reducing the partial onset seizure frequency and that pregabalin will be safe and well tolerated.

NCT ID: NCT02072564 Completed - Lifestyle Factors Clinical Trials

Influence of Diet and Lifestyle Factors on the Results of the IVF

Start date: November 2013
Phase: N/A
Study type: Observational [Patient Registry]

The purpose of this study is study the possible relationship between various lifestyle habits of men and women (age, body mass index, diet, exercise, alcohol, tobacco, coffee, etc..) and live birth rate after in vitro fertilization-intracytoplasmatic injection (IVF-ICSI).

NCT ID: NCT02072434 Completed - Atrial Fibrillation Clinical Trials

Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)

ENSURE-AF
Start date: March 25, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare edoxaban to warfarin (with enoxaparin, if needed). It will see if edoxaban prevents stroke and other blood clotting problems as well and as safely as warfarin. People with atrial fibrillation (irregular heartbeat) might be able to join. Their doctors must plan to use shock to make their hearts beat normally. About 2200 people from different countries will join. They will have an equal chance of receiving either treatment. They are anticipated to be in the study for around 82 days. Tests will include physicals and finger-pricks. Participants will provide blood and urine samples.